Abstract
We designed a unique regimen of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and recombinant interleukin 2 (rIL-2) for application with surgical adjuvant therapy of cancer. The regimen features the prolonged (6 consecutive days) s.c. administration of low-dose rIL-2 and the transfer ofex vivo generated LAK cells from regional lymph node lymphocytes, obtained at the time of surgical operation. According to this regimen, 5 patients with primary lung cancer received immunotherapy about 2 weeks after surgery (pulmonary lobectomy). Clinical toxicities included fever(5/5), fatigue(5/5), slight(< 5%) weight gain(5/5), increase of pleural effusion at the lobectomy site(2/5), and edema formation(1/5). All toxicities reversed within 4 days after the completion of therapy. Rebound lymphocytosis after therapy ranged from 2.4 to 5.5-fold (mean, 4.3-fold) over the baseline. Peripheral blood lymphocytes obtained during this lymphocytosis exhibitedin vitro LAK activity in 4 of 5 patients. Thus, the regimen is considered to be well-tolerable and immunologically active in regard to the postoperative state of the patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenberg SA, Lotze MT, Muul ML, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto IT, Seipp CA, Simpson CG, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.
Rosenberg SA, Lotze MT, Muul ML, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–97.
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905.
Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 1988; 208: 121–35.
Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, Hawkins MJ, Atkins MB, Ciobanu N, Ellis TM. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res 1988; 48: 4409–16.
Kato K, Yamada T, Kawahara K, Onda H, Asano T, Sugino H, Kakinuma A. Purification and characterization of recombinant human interleukin-2 produced inEscherichia coli. Biochem Biophys Res Commun 1985; 130: 692–9.
Yano T, Yasumoto K, Togami M, Ishida T, Kimura G, Sugimachi K, Nomoto K. Properties of recombinant interleukin 2-cultured tumor-infiltrating lymphocytes in human lung cancer. Int J Cancer 1989; 43: 619–23.
Moriya N, Kato K, Suzuki N, Yamada T, Nishimura O. An enzyme-immunoassay for human interleukin-2. J Immunoassay 1987; 8: 131–43.
Yano T, Yasumoto K, Nomoto K. Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer. Eur J Cancer Clin Oncol 1989; 25: 201–8.
Murata M, Yano T, Togami M, Yasumoto K, Sugimachi K, Kimura G, Nomoto K. Development of a new culture system for human lymphokine-activated killer cells. J Immunol Methods 1990; 129: 89–95.
Yano T, Murata M, Ishida T, Mitsudomi T, Kimura G, Sugimachi K, Nomoto K. Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes. Cell Immunol 1989; 122: 578–84.
Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6: 669–78.
Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 1989; 49: 235–40.
Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cellsin vivo with recombinant IL-2. J Immunol 1985; 135: 2865–75.
Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sondel PM.In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res 1988; 48: 1965–71.
Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NC, Sosman JA, Bechhofer R, Storer B. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988; 48: 2561–7.
Mitchell MS, Kempf RA, Harel W, Shaw H, Boswell WD, Lind S, Bradley EC. Effectiveness and tolerability of lowdose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988; 6: 409–24.
Walewski J, Paietta E, Dutcher J, Wiernik PH. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activityin vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells. J Cancer Res Clin Oncol 1989; 115: 170–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yano, T., Ishida, T., Yoshino, I. et al. A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Biotherapy 3, 245–251 (1991). https://doi.org/10.1007/BF02171688
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02171688